These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1720 related items for PubMed ID: 24139932

  • 1. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, Costa JR, Chamie D, Abizaid AS, Pinto I, Morrison L, Toyloy S, Bhat V, Yan J, Abizaid A.
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [Abstract] [Full Text] [Related]

  • 2. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W.
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [Abstract] [Full Text] [Related]

  • 3. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
    Abizaid A, Costa RA, Schofer J, Ormiston J, Maeng M, Witzenbichler B, Botelho RV, Costa JR, Chamié D, Abizaid AS, Castro JP, Morrison L, Toyloy S, Bhat V, Yan J, Verheye S.
    JACC Cardiovasc Interv; 2016 Mar 28; 9(6):565-74. PubMed ID: 27013155
    [Abstract] [Full Text] [Related]

  • 4. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia-Garcia HM, Ormiston JA, Serruys PW.
    JACC Cardiovasc Interv; 2013 Oct 28; 6(10):999-1009. PubMed ID: 24156961
    [Abstract] [Full Text] [Related]

  • 5. One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the NeoVas bioresorbable sirolimus-eluting scaffold in patients with single de novo coronary artery lesions.
    Wang XZ, Zhang YJ, Fu GS, Jing QM, Xu B, Han YL.
    Catheter Cardiovasc Interv; 2018 Feb 15; 91(S1):617-622. PubMed ID: 29392879
    [Abstract] [Full Text] [Related]

  • 6. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
    Wang G, Sun Z, Jin Q, Xu K, Li Y, Wang X, Ma Y, Liu H, Zhao X, Wang B, Deng J, Guan S, Ge M, Wang X, Xu B, Han Y.
    Catheter Cardiovasc Interv; 2015 Mar 15; 85 Suppl 1():744-51. PubMed ID: 25630447
    [Abstract] [Full Text] [Related]

  • 7. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia-Garcia HM.
    Circ Cardiovasc Interv; 2012 Oct 15; 5(5):620-32. PubMed ID: 23048057
    [Abstract] [Full Text] [Related]

  • 8. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F, Romano M, Rosiello R, La Vecchia L, Cabianca E, Caramanno G, Milazzo D, Loschiavo P, Rigattieri S, Musarò S, Pironi B, Fiscella A, Amico F, Indolfi C, Spaccarotella C, Bartorelli A, Trabattoni D, Della Rovere F, Rolandi A, Beqaraj F, Belli R, Sangiorgio P, Villani R, Berni A, Sheiban I, Lopera Quijada MJ, Cappi B, Ribaldi L, Vassanelli C, EXECUTIVE Trial Investigators.
    JACC Cardiovasc Interv; 2013 Oct 15; 6(10):1012-22. PubMed ID: 24055444
    [Abstract] [Full Text] [Related]

  • 9. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.
    Han Y, Xu B, Fu G, Wang X, Xu K, Jin C, Tao L, Li L, Hou Y, Su X, Fang Q, Chen L, Liu H, Wang B, Yuan Z, Gao C, Zhou S, Sun Z, Zhao Y, Guan C, Stone GW, NeoVas Randomized Controlled Trial Investigators.
    JACC Cardiovasc Interv; 2018 Feb 12; 11(3):260-272. PubMed ID: 29413240
    [Abstract] [Full Text] [Related]

  • 10. Clinical and multimodality imaging results at 6 months of a bioresorbable sirolimus-eluting scaffold for patients with single de novo coronary artery lesions: the NeoVas first-in-man trial.
    Zhang YJ, Wang XZ, Fu G, Jing QM, Wang G, Jin CY, Xie LH, Cai JZ, Xu B, Han YL.
    EuroIntervention; 2016 Nov 20; 12(10):1279-1287. PubMed ID: 27866137
    [Abstract] [Full Text] [Related]

  • 11. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia HM, Veldhof S, Rapoza R, Ormiston JA.
    JACC Cardiovasc Interv; 2014 Dec 20; 7(12):1400-11. PubMed ID: 25523532
    [Abstract] [Full Text] [Related]

  • 12. Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery.
    Wu Y, Shen L, Ge L, Wang Q, Qian J, Zhang F, Yao K, Huang D, Chen Y, Ge J.
    Catheter Cardiovasc Interv; 2016 Mar 20; 87 Suppl 1():630-7. PubMed ID: 26864162
    [Abstract] [Full Text] [Related]

  • 13. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.
    Xu B, Dou K, Yang Y, Lv S, Wang L, Wang H, Li Z, Wang L, Chen Y, Huo Y, Li W, Kirtane AJ, Gao R.
    EuroIntervention; 2012 Nov 22; 8(7):796-802. PubMed ID: 23171800
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial.
    Arroyo D, Togni M, Puricel S, Gerard B, Sonja L, Corpataux N, Villeneuve H, Boute E, Stauffer JC, Goy JJ, Cook S.
    Trials; 2014 Jan 07; 15():9. PubMed ID: 24398143
    [Abstract] [Full Text] [Related]

  • 17. A multicenter post-marketing evaluation of the Elixir DESolve® Novolimus-eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study.
    Nef H, Wiebe J, Boeder N, Dörr O, Bauer T, Hauptmann KE, Latib A, Colombo A, Fischer D, Rudolph T, Foin N, Richardt G, Hamm C.
    Catheter Cardiovasc Interv; 2018 Nov 15; 92(6):1021-1027. PubMed ID: 29508518
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
    Tenekecioglu E, Serruys PW, Onuma Y, Costa R, Chamié D, Sotomi Y, Yu TB, Abizaid A, Liew HB, Santoso T.
    JACC Cardiovasc Interv; 2017 Jun 12; 10(11):1115-1130. PubMed ID: 28527768
    [Abstract] [Full Text] [Related]

  • 20. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2013 Aug 12; 6(8):777-89. PubMed ID: 23968698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 86.